<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title xml:lang="ru">Антибиотики и Химиотерапия</journal-title><trans-title-group xml:lang="en"><trans-title>Antibiot Khimioter = Antibiotics and Chemotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0235-2990</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1016/0235-2990-2019-64-11-12-3-7</article-id><article-id custom-type="elpub" pub-id-type="custom">antibiotics-161</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL PAPERS</subject></subj-group></article-categories><title-group><article-title>4,4а-дигидроксантоны как перспективные соединения для создания новых антимикробных препаратов</article-title><trans-title-group xml:lang="en"><trans-title>4,4A-Dihydroxanthones as Promising Compounds for Creation of New Antimicrobials</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фролова</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Frolova</surname><given-names>V. V.</given-names></name></name-alternatives><email xlink:type="simple">Zhilyaeva.valeriya@pharminnotech.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гурина</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gurina</surname><given-names>S. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чернов</surname><given-names>Н. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Chernov</surname><given-names>N. M.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яковлев</surname><given-names>И. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakovlev</surname><given-names>I. P.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Санкт-Петербургский государственный химико-фармацевтический университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint Petersburg State Chemical Pharmaceutical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>06</day><month>05</month><year>2020</year></pub-date><volume>64</volume><issue>11-12</issue><fpage>3</fpage><lpage>7</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Фролова В.В., Гурина С.В., Чернов Н.М., Яковлев И.П., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Фролова В.В., Гурина С.В., Чернов Н.М., Яковлев И.П.</copyright-holder><copyright-holder xml:lang="en">Frolova V.V., Gurina S.V., Chernov N.M., Yakovlev I.P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.antibiotics-chemotherapy.ru/jour/article/view/161">https://www.antibiotics-chemotherapy.ru/jour/article/view/161</self-uri><abstract><p>С целью прогнозирования биологической активности новых производных 4,4а-дигидроксантона была использована компьютерная программа PASS (Prediction of Activity Spectra for Substances), позволяющая предсказать спектр биологической активности химических соединений на основе анализа взаимосвязей «структура-активность». Производные 4,4а-дигидроксантона были синтезированы на кафедре органической химии Санкт-Петербургского государственного химикофармацевтического университета. В результате проведённого скрининга установлено, что 4,4а-дигвдроксантоны могут проявлять антибактериальное, противогрибковое, противоопухолевое, противовирусное действие. Антимикробная активность полученных соединений была изучена в отношении грамположительных и грамотрицательных бактерий, а также грибов. Показано, что дигидроксантоны оказывали ингибирующее действие на грамположительные бактерии. Установлена взаимосвязь между строением производных и их противомикробной активностью. Наличие электроноакцепторных заместителей приводило к повышению активности, а электронодонорные заместители снижали антибактериальный эффект соединений. Было выявлено наиболее активное соединение - 5-бром-7-хлор-4,4а-дигидроксантон - обладающее активностью в отношении некоторых клинических штаммов стафилококков.</p></abstract><trans-abstract xml:lang="en"><p>In order to predict the biological activity of the new derivatives of 4,4a-dihydroxanthone, the PASS (Prediction ofActivity Spectra for Substances) computer program was used. It allows predicting the biological activity spectrum of chemical compounds based on the analysis of structure-activity interrelation. Derivatives of 4,4a-dihydroxanthone were synthesized at the Department of Organic Chemistry of the Saint Petersburg State Chemical Pharmaceutical University. As a result of the screening, it was found that 4,4a-dihydroxanthones can exhibit antibacterial, antifungal, antitumor, and antiviral effects. Antimicrobial activity of the obtained compounds was studied against Gram-positive and Gram-negative bacteria, as well as fungi. Dihydroxanthones were shown to have an inhibitory effect on Gram-positive bacteria. Relationship between the structure of derivatives and their antimicrobial activity is established. The presence of electron-withdrawing substituents led to an increase in activity, and electron-donating substituents reduced the antibacterial effect of the compounds. The most active compound, 5-bromo-7-chloro-4,4a-dihydrox-anthone, was found to be active against certain clinical strains of staphylococci.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ксантоны</kwd><kwd>дигидроксантоны</kwd><kwd>противомикробная активность</kwd><kwd>структура-активность</kwd><kwd>клинические штаммы стафилококков</kwd></kwd-group><kwd-group xml:lang="en"><kwd>VITEK2 COMPACT60</kwd><kwd>xanthones</kwd><kwd>dihydroxanthones</kwd><kwd>antimicrobial activity</kwd><kwd>structure-activity</kwd><kwd>clinical strains of staphylococci</kwd><kwd>VITEK 2 COMPACT 60</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
